William Drobyski, M.D.
Professor of Medicine
William Drobyski, M.D. is a Professor in the Departments of Medicine, Pediatrics and Microbiology and Molecular Genetics. He completed his medical school, internal medicine residency, and hematology fellowship training at the University of Rochester. He obtained his fellowship training in bone marrow transplantation at the Medical College of Wisconsin before joining the faculty in 1990. His primary clinical interests are in the areas of allogeneic hematopoietic stem cell transplantation and immunotherapy. He also has a basic research laboratory that focuses on the pathophysiology of graft versus host disease and has been continuously funded by the National Institutes of Health (NIH) for the past 22 years. Dr. Drobyski has also served on numerous NIH study sections and is currently on the editorial board of the journal Biology of Blood and Marrow Transplantation.
1. Cohen EP, Drobyski WR and Moulder JE. Sixteen-fold increase in end stage renal disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 39: 571-572, 2007.
2. Gorski J, Chen X, Gendelman M, Yassai M, Krueger A, Tivol E, Logan B, Komorowski R, Vodanovic-Jankovic S, and Drobyski WR. Homeostatic expansion and repertoire regeneration of donor T cells during graft versus host disease is constrained by the host environment. Blood 109: 5502-5510, 2007.
3. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft versus host disease. Blood 110: 3804-3813, 2007.
Recognized by Inside Blood Commentary
Recognized by Faculty 1000 Biology as a recommended paper of interest August 24, 2007; http://www.f1000biology.com/article/id/1089415
4. Cohen EP, Irving AA, Drobyski WR, Klein JP, Passweg J, Talano JM, Juckett MB, and Moulder JE. Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. Int J Rad Oncol Biol Phys 70: 1546-1551, 2008.
5. Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N, Fort J, Loberiza F, Porter D, Giralt S, Drobyski W, Wang D, Pavletic S, Ringden O, Horowitz M, Collins R. Donor leukocyte infusions to treat hematologic malignancy relapse after allogeneic stem cell transplantation in a pediatric population. Bone Marrow Transplant 42:201-205, 2008.
6. Drobyski WR, Hari P, Keever-Taylor CA, Komorowski R, Grossman W. Severe autologous graft versus host disease after hematopoietic progenitor cell transplantation for multiple myeloma. Bone Marrow Transplant 43: 169-177, 2009.
7. Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR. Interleukin 23 secretion by donor antigen presenting cells is critical for organ-specific pathology in graft versus host disease. Blood 113: 2352-2362, 2009.
8. Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M, Drobyski WR. Blockade of interleukin 6 signaling augments regulatory T cell reconstitution and attenuates the severity of graft versus host disease. Blood 2009; 114: 891-900.
Recognized by Faculty 1000 Biology as a recommended paper of interest June 9, 2009; http://www.f1000biology.com/article/id/1161030
9. Filicko-O’Hara J, Filicko J, Grosso D, Flomenberg PR, Friedman TM, Brunner J, Drobyski W, Ferber A, Kahkniashvili I, Keever-Taylor C, Moorkerjee B, Talano J,A, Wagner JL, Korngold R, Flomenberg N. Anti-viral responses following LLME-treated lymphocyte infusions: Graft versus infection without graft versus host disease. Biol Blood Marrow Transplant 15: 1609-1619, 2009.
10. Chen X, Das R, Komorowski R, van Snick J, Uyttenhove C, Drobyski WR. Interleukin 17 is not required for autoimmune-mediated pathological damage during chronic graft versus host disease. Biol Blood Marrow Transplant 16: 123-128, 2010.
11. Johnson B, Drobyski W, Blazar B, Korngold R. Robert Truitt Tribute. Biol Blood Marrow Transplant 16: 143-144, 2010.
12. Sukumaran S, George B, Nair H, Drobyski WR. Posterior reversible encephalopathy syndrome in association with high dose steroids after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 45:779-80, 2010.
13. Gress RE, Emerson SG, Drobyski WR. Immune reconstitution: How it should work, what’s broken, and why it matters. Biol Blood Marrow Transplant 16: S133-S137, 2010.
14. Das R, Komorowski R, Hessner MJ, Subramanian H, Huettner CS, Cua D, Drobyski WR. Blockade of interleukin 23 signaling results in targeted protection of the colon and allows for separation of graft versus host and graft versus leukemia responses. Blood 115: 5249-5258, 2010.
15. Cogbill CH, Drobyski WR, Komorowski RA. Gastrointestinal pathology of autologous graft versus host disease following hematopoietic stem cell transplantation: a clinicopathologic study of 17 cases. Mod Pathol 24: 117-125, 2011.
16. Hallett WHD, Jing W, Drobyski WR, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant 17: 1133-1145, 2011.
17. Beres A, Komorowski R, Mihara M, Drobyski WR. Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease. Clin Cancer Res 17: 3969-3983, 2011.
18. Drobyski WR, Pasquini M, Kovatovic K, Palmer J, Rizzo JD, Saad A, Saber W, Hari P. Tocilizumab for the treatment of steroid refractory graft versus host disease. Biol Blood Marrow Transplant 17: 1862-1868, 2011.
19. Weisdorf D, Cooley S, Devine S, Fehninger T, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, deFor T, Haagenson M. Curtsinger J, Miller J. T cell depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. Biol Blood Marrow Transplant 18: 937-943, 2012.
20. Cornell RF, Palmer J, Komorowski RA, Drobyski WR. Surgical resection as definitive treatment for refractory graft versus host disease of the colon. Bone Marrow Transplant 2012 (in press).
21. Battiwalla M, Ellis K, Li P, Pavletic SZ, Akpek G, Hematti P, Klumpp TR, Maziarz RT, Savani B, Aljurf MD, Cairo MS, Drobyski W, George B, Hahn T, Khera N, Litzow MR, Loren AW, Saber W, Arora M, Urbano A, Cutler C, Flowers MED, Spelleman SR. HLA DR15 antigen status does not impact graft versus host disease or disease-free survival in HLA-matched sibling transplantation for hematologic malignancies. Biol Blood Marrow Transplant 18: 1302-1308, 2012.
22. Rangarajan H, Yassai M, Subramanian H, Chen X, Komorowski R, Whitaker M, Gorski J, Drobyski WR. Emergence of T cells that recognize non polymorphic antigens during graft versus host disease. Blood 119: 6354-6364, 2012.
Recognized by Inside Blood Commentary
23. Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, Drobyski WR. CD8+ Foxp3+ regulatory T cells are induced during graft versus host disease and mitigate disease severity. J Immunol 189: 464-474, 2012.
24. Beres AJ, Drobyski WR. Recent pre-clinical advancements in the treatment of acute graft versus host disease. J Clin Immunol 2012 (in press).
Best Doctors® logo is registered trademark of Best Doctors, Inc. in the United States and other countries.